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Endosomal NOX2 oxidase exacerbates virus
pathogenicity and is a target for antiviral therapy
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The imminent threat of viral epidemics and pandemics dictates a need for therapeutic
approaches that target viral pathology irrespective of the infecting strain. Reactive oxygen
species are ancient processes that protect plants, fungi and animals against invading
pathogens including bacteria. However, in mammals reactive oxygen species production
paradoxically promotes virus pathogenicity by mechanisms not yet deﬁned. Here we identify
that the primary enzymatic source of reactive oxygen species, NOX2 oxidase, is activated by
single stranded RNA and DNA viruses in endocytic compartments resulting in endosomal
hydrogen peroxide generation, which suppresses antiviral and humoral signaling networks via
modiﬁcation of a unique, highly conserved cysteine residue (Cys98) on Toll-like receptor-7.
Accordingly, targeted inhibition of endosomal reactive oxygen species production abrogates
inﬂuenza A virus pathogenicity. We conclude that endosomal reactive oxygen species
promote fundamental molecular mechanisms of viral pathogenicity, and the speciﬁc targeting
of this pathogenic process with endosomal-targeted reactive oxygen species inhibitors has
implications for the treatment of viral disease.
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The production of reactive oxygen species (ROS) is a highlycoordinated process achieved by enzymes of the NADPHoxidase (NOX) family. NOX enzymes are not present in
prokaryotes but evolved ~1.5 billion years ago in single cell
eukaroytes and are present in most eukaryotic groups including
ameba, fungi, algae and plants, nemotodes, echinoderms,
urochordates, insects, ﬁsh, reptiles and mammals1, 2. The
functions of NADPH oxidases within eukaryotes are diverse,
however, a common function is the generation of ROS by
innate immune cells in response to pathogens. Indeed, orthologs
of NADPH oxidase in plants (ArtbohD and ArtbohF), fungi
(NOXA/B), and invertebrates Caenorhabditis elegans
(Duox orthologs), Drosophila melongaster (NOX5 homolog,
d-NOX, and DUOX) and mosquito Aedes aegypti (NOXM and
DUOX) generate ROS with bactericidal activity that protects the
host1, 2. Vertebrates including teleosts, amphibians, birds, and
mammals possess a NOX2 NADPH oxidase that generates a burst
of ROS within phagosomes to kill invading pathogens especially
bacteria. However, the impact of ROS on virus infection is largely
unknown.
ROS, such as superoxide anion and hydrogen peroxide (H2O2),
are produced by mouse and human inﬂammatory cells in
response to viral infection and enhance the pathology caused by
viruses of low to high pathogenicity, including inﬂuenza A
viruses3–8. The primary source of inﬂammatory cell ROS is the
NOX2 oxidase enzyme8–11. Although NOX2 oxidase plays a
role in the killing of bacteria and fungi via phagosomal ROS
production, NOX2 oxidase does not appear to eliminate viruses
in a manner analogous to that for bacteria. In fact, in the absence
of NOX2, inﬂuenza A virus causes substantially less lung injury
and dysfunction, and leads to lower viral burden suggesting that
NOX2 oxidase-derived ROS promotes rather than inhibits viral
infection3–8. However, it remains unknown how viruses cause
ROS production and how these highly reactive oxygen molecules,
which appear to be largely conﬁned to their site of generation,
contribute to disease.
After binding to the plasma membrane12, viruses enter cells
and ultimately endosomes by a variety of mechanisms resulting in
viral RNA detection by endosomal pattern recognition receptors,
including toll-like receptor 3 (TLR3), TLR7, and TLR913. The
speciﬁc receptor interaction depends upon either the Group (I–V)
or genomic orientation (i.e., ssRNA, dsRNA or DNA) of the virus
and triggers an immune response characterized by Type I IFN
and IL-1β production, and B-cell-dependent antibody produc-
tion13. Host nucleic acids and self-antigens are also detected by
endosomal TLRs, and in autoimmune disease, mediate similar
Type I IFN responses and stimulate antibody production against
self-RNA and antigen. Notably, mice that are chronically deﬁcient
in NOX2 oxidase have an increased tendency to develop self-
antibodies14 and patients with chronic granulomatous disease,
who have a defective capacity to generate ROS via the NOX2
oxidase, have elevated circulating Type I IFNs and auto-
antibodies15. These observations are supportive of the notion that
low levels of ROS result in an enhanced immune response.
However, it remains unknown how ROS modulates inﬂammation
and the pathology caused by viruses and whether targeted (and
acute) abrogation of ROS may actually be beneﬁcial in treating
viral infection.
Here we hypothesize ﬁrstly, that the internalization of virus
into endosomes results in ROS production and that this subdues
essential immune pathways that would otherwise clear the virus;
and secondly that the targeted inhibition of endosomal ROS
markedly reduces viral pathogenicity. The identiﬁcation of a
mechanism to explain the paradoxical effect of ROS on viruses vs.
other pathogens such as bacteria has the potential to facilitate the
development of speciﬁc endosome-targeted antiviral therapies.
Our results demonstrate that, NOX2 oxidase is expressed in
endosomes in mouse and human cells, and is activated following
infection with a) single stranded RNA viruses irrespective of their
classiﬁcation including inﬂuenza A viruses, respiratory syncytial
virus, rhinovirus, Dengue virus and HIV, as well as b) the DNA
viruses vaccinia virus and herpes simplex virus. Activation of
endosomal NOX2 is dependent on TLR7 for ssRNA viruses or
TLR9 for DNA viruses and is the result of PKC activation.
Endosomal NOX2 oxidase activity results in the spatially targeted
generation of H2O2, which suppresses key antiviral and humoral
signaling processes via the modiﬁcation of a unique, highly
conserved single cysteine residue (Cys98) on the ectodomain of
TLR7. Accordingly, targeting endosomal ROS production with a
NOX2 oxidase inhibitor suppresses inﬂuenza A virus patho-
genicity. Finally these ﬁndings identify four conceptual
advancements centered on ROS biology including: (1) identiﬁ-
cation of the endosome as a critical sub cellular compartment of
ROS generation to virus infection, irrespective of strain; (2)
molecular targets of ROS reside within the endosome revealing a
paradigm in organelle-speciﬁc cell signaling; (3) endosomal ROS
suppress antiviral signaling, and (4) endosome speciﬁc delivery of
a ROS inhibitor is an effective treatment strategy for inﬂuenza
viral disease.
Results
Inﬂuenza viruses drive endosomal ROS. To address the
potential role of endosomal ROS production in virus pathology
we ﬁrst focussed on inﬂuenza A viruses, which belong to the
Group IV negative sense, ssRNA viruses of the Orthomyxoviridae
family and are internalized by endocytosis. Exposure of mouse
alveolar macrophages (AMs), mouse peritoneal RAW264.7 cells
or bone marrow-derived macrophages (BMDMs) to inﬂuenza
A virus strain HKx31 (H3N2) resulted in a dose and
time-dependent increase in inﬂuenza nucleoprotein (NP)
ﬂuorescence (Supplementary Fig. 1a), which was almost abolished
by the dynamin inhibitor, Dynasore (100 μM) indicating
a clathrin-coated pit or caveolin-dependent mechanism of
internalization (Supplementary Fig. 1b). Internalized virus
displayed a strong co-location with the early endosomal marker
EEA1 (Fig. 1a). However, not all of the NP was co-located
with EEA1 indicating that inﬂuenza A virus was not present
exclusively in early endosomes (Fig. 1a) and might have already
entered late endosomes and/or lysosomes. NOX2 co-located
with EEA1 in control and inﬂuenza infected cells (Fig. 1b,
Supplementary Fig. 1c). Thus, the enzymatic machinery for ROS
generation is present in early endosomes and this is signiﬁcantly
enhanced in inﬂuenza A virus infection, promoting
co-localization with internalized virus.
Endosomal ROS production in response to viral uptake was
assessed with OxyBURST16. Exposure to a series of low to high
pathogenic seasonal and pandemic inﬂuenza A viruses resulted in
rapid and dose-dependent increases in OxyBURST ﬂuorescence
in mouse primary AMs (Fig. 1c, d, Supplementary Fig. 2a, b, e, f)
and human AMs (Fig. 1h). This OxyBURST-derived signal was
abolished by addition of superoxide dismutase (SOD; 300 U/ml),
which internalizes into the endosome along with the virus17 and
converts superoxide to H2O2 (Fig. 1e, f). In contrast the ROS
signal was signiﬁcantly increased in AMs from mice deﬁcient
in endosomal SOD (SOD3−/− mice), establishing the detection
of a superoxide derivative (Supplementary Fig. 2c, d).
For conﬁrmation that ROS production occurred in acidiﬁed
endosomes we demonstrated a co-location of OxyBURST
ﬂuorescence with LysoTracker (50 nM) in the presence of
inﬂuenza virus (Fig. 1g). Inhibition of the vacuolar V-ATPase
pump with baﬁlomycin A (100 nM), and thus inhibition of
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endosomal acidiﬁcation, abolished the LysoTracker ﬂuorescence
and endosomal ROS production in response to inﬂuenza A virus
infection (Fig. 1g). Endosomal ROS was minimal in NOX2−/y
AMs, but was unaffected in NOX4−/− macrophages and in
macrophages treated with the NOX1 inhibitor ML171 (100 nM)
(Fig. 1e, f, Supplementary Fig. 2h, i). Internalization of inﬂuenza
A virus into AMs was not impaired in NOX2−/y cells
(Supplementary Fig. 2g), indicating that reduced endosomal
ROS production was not due to reduced viral entry. In addition,
heat- and UV-inactivated forms of inﬂuenza (replication-
deﬁcient) caused an increase in endosomal ROS production that
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inﬂuenza A viruses, irrespective of subtype, strain and
pathogenicity, stimulate NOX2, but not NOX4 or NOX1
oxidase-dependent ROS production in endosomes, and this
involves endosomal acidiﬁcation, but does not require viral
replication.
Endosome TLR7-NOX2 signaling axis. RNA viruses are
recognized by endosomal TLR7 (for ssRNA viruses)18, 19 and
TLR3 (dsRNA viruses), as well as the cytosolic sensors retinoic
acid inducible gene I (RIG-I) (which can detect viral RNA bearing
5′ triphosphates18 and NOD-like receptors (NLRs)13, 20, 21.
We hypothesized that inﬂuenza A virus entry into acidiﬁed
endosomes results in the liberation of viral RNA, activation of
TLR7 and stimulation of NOX2 oxidase-dependent ROS
production. Consistent with this suggestion, TLR7 co-locates with
inﬂuenza A virus (Fig. 2a), NOX2 (Fig. 2b) and EEA1 (Fig. 2c,
Supplementary Fig. 3a) and primary AMs from TLR7−/− mice,
and TLR7- and MyD88-deﬁcient BMDM, display minimal
endosomal ROS production in response to inﬂuenza A virus
(Fig. 2d, Supplementary Fig. 3b–e). The lack of endosomal ROS
production in response to virus in TLR7−/− and MyD88−/− cells
was not due to a reduced capacity of the NOX2 oxidase per se, as
NOX2 activation by the PKC activator phorbol dibutyrate (PDB;
10−6 M) was similar in these cells and wild-type (WT) control
cells (Supplementary Fig. 3c). As a second measure of NOX2
oxidase activity, we assessed enzyme assembly by examining the
degree of association of the NOX2 catalytic subunit with the
p47phox regulatory subunit. In unstimulated cells, there was very
little co-localization of NOX2 and p47phox (Fig. 2e). However,
inﬂuenza virus caused strong co-location of NOX2 and p47phox,
which was reduced by Dynasore or baﬁlomycin A pre-treatment,
and almost abolished in TLR7−/− cells (Fig. 2e). To provide
further evidence that the activation of TLR7 leads to endosomal
ROS production, we used the speciﬁc TLR7 agonist, imiquimod
(10 μg/ml). Imiquimod markedly increased endosomal ROS in
AMs from human and WT mice, but not from NOX2−/y mice
(Fig. 2f) or macrophages deﬁcient in TLR7 or MyD88
(Supplementary Fig. 3b). Finally, we pulsed AMs or RAW264.7
cells with a guanidine- and uridine-rich ssRNA sequence
(ssRNA40; 100 μM). In concentrations capable of increasing
IL-1β, IL-6, and TNF-α mRNA via a TLR7-dependent
mechanism (Supplementary Fig. 4), ssRNA40 caused elevated
endosomal ROS production (Fig. 2g). In contrast, endosomal
ROS production in response to inﬂuenza A virus was preserved in
RIG-I−/−, NLRP3−/−, TLR2−/−, and TLR4−/− macrophages, and
in macrophages treated with the TLR3 inhibitor (50 μM)
(Supplementary Fig. 3d–h).
We subsequently examined how TLR7 elicits the assembly and
activation of endosomal NOX2 oxidase. NOX2 oxidase can be
activated by protein kinase C, which triggers robust
phosphorylation of key serine residues on p47phox, resulting in
a NOX2 oxidase-dependent oxidative burst10. To deﬁne the
spatiotemporal regulation of PKC signaling and to assess its
regulation by TLR7, we expressed the FRET biosensor cytoCKAR,
to detect cytosolic PKC22–24 in WT and TLR7−/− macrophages.
The treatment of WT macrophages with inﬂuenza A virus or
imiquimod elevated cytosolic PKC activity within 5 min, but this
response was absent in TLR7−/− macrophages and in WT
macrophages treated with Dynasore or baﬁlomycin A (Fig. 2h, i).
A FRET biosensor method for cytosolic pERK1/2 activity21, 24
showed that both inﬂuenza virus and imiquimod increased
cytosolic pERK1/2 in a TLR7-dependent manner. In contrast,
blocking pERK1/2 with PD98059 (30 μM) did not inﬂuence
endosomal ROS production (Supplementary Fig. 5a, b) or the
association of NOX2 with p47phox in response to inﬂuenza
(Supplementary Fig. 5c). These data indicate that inﬂuenza A
virus increases endosomal NOX2 oxidase activity via TLR7 and
the downstream activation of PKC but not via pERK1/2.
We conclude that virus infection triggers a NOX2
oxidase-dependent production of ROS in endosomes using a
process that is dependent on low pH. Indeed this conclusion
is supported by the following experimental evidence. First it
is known that reduced endosome acidiﬁcation impairs the
activation of TLR7 by viral RNA18, 19. Our study is in agreement
with this ﬁnding, showing that NOX2 dependent ROS production
to virus infection and to the TLR7 agonist imiquimod was
abolished in TLR7−/− cells and also by pretreatment with
baﬁlomycin A. Second, baﬁlomycin A suppressed PKC activation
due to inﬂuenza virus and imiquimod treatment, and PKC is
upstream of acute NOX2 activation10, 11. Third, baﬁlomycin
A suppressed the association of p47phox-NOX2, which is a
critical step for NOX2 assembly and activation.
Viral strain independence of endosomal ROS. Exposure
of macrophages to rhinovirus (picornaviridae, Group IV),
respiratory syncytial virus (paramyxoviridae, Group V), human
parainﬂuenza virus (paramyxoviridae, Group V), human
metapneumovirus (paramyxoviridae, Group V), Sendai virus
(paramyxoviridae, Group V), Dengue virus (ﬂavoviridae Group
IV) or HIV (retroviridae, Group VI, ssRNA-RT virus) resulted in
a signiﬁcant elevation of endosomal ROS that was markedly
suppressed in TLR7−/− macrophages, but unaffected in TLR9−/−
cells (Fig. 3a, b). Both mumps virus (paramyxoviridae Group V)
and Newcastle disease virus (NDV, paramyxoviridae Group V)
failed to generate signiﬁcant endosomal ROS (Fig. 3a, b), and it
is noteworthy that these viruses primarily enter cells by a
cell membrane fusion process and not via endocytosis.
Rotavirus (rhesus monkey strain or bovine UK strain,
Fig. 1 Seasonal and pandemic inﬂuenza A viruses induce endosomal ROS production via activation of NOX2 oxidase. a, b Confocal microscopy of wild-type
(WT) mouse primary alveolar macrophages that were infected with inﬂuenza A virus strain HKx31 (MOI of 10) for 1 h and labeled with antibody to the
early endosome antigen 1 (EEA1) and antibodies to either a inﬂuenza A virus nucleoprotein (NP) or b NOX2, and then with 4′,6′-diamidino-2-phenylindole
(DAPI; blue). Also shown is the quantiﬁcation of results (n= 5). c, d Time-dependent elevation in endosomal ROS levels in mouse primary alveolar
macrophages as assessed by OxyBURST (100 μM) confocal ﬂuorescence microscropy and labeled with DAPI (n= 5). e, f Endosomal ROS production in
WT, NOX2−/y and superoxide dismutase (SOD; 300 U/ml)-treated WT mouse primary alveolar macrophages as assessed by OxyBURST confocal
ﬂuorescence microscopy in the absence or presence of HKx31 virus and labeled with DAPI (n= 5). g Uninfected and HKx31 virus-infected mouse primary
alveolar macrophages were labeled with OxyBURST and the acidiﬁed endosome marker Lysotracker (50 nM). Some cells were treated with baﬁlomycin A
(Baf-A; 100 nM) to suppress acidiﬁcation of endosomes (n= 4). h Human alveolar macrophages infected with seasonal H3N2 (A/New York/55/2004, A/
Brisbane/9/2007), seasonal H1N1 (A/New Caledonia/20/1999, A/Solomon Islands/3/2006) and pandemic A(H1N1) pdm09 strains (A/California/7/
2009, A/Auckland/1/2009) and labeled with OxyBURST for endosomal ROS (n= 4). i, j Endosomal ROS production in WT mouse primary alveolar
macrophages as assessed by OxyBURST ﬂuorescence microscopy exposed to either heat (56 ºC)-inactivated HKx-31 virus (to block virus fusion) or UV-
inactivated HKx-31 virus (to block replication) and labeled with DAPI (n= 4). a–i Images are representative of >150 cells analyzed over each experiment.
Original magniﬁcation ×100. a, b, d, f and j Data are represented as mean± S.E.M. a and b Students’ unpaired t-test *P< 0.05. d, f and j One-way ANOVA
followed by Dunnett’s post hoc test for multiple comparisons. *P< 0.05 and **P< 0.01. Scale bars: 10 µm
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(reoviridae Group III)) exposure of macrophages also failed to
generate endosomal ROS (Fig. 3a, b). The DNA viruses Herpes
simplex virus 2 (herpesviridae, Group I) and vaccinia virus
(poxyviridae, Group I) each caused an elevation in endosomal
ROS in WT macrophages and TLR7−/− macrophages, but not
in TLR9−/− macrophages (Fig. 3a, b). We conclude that the
speciﬁc recognition of either ssRNA viruses by TLR7, or DNA
viruses by TLR9, leads to a NOX2 oxidase-dependent burst of
endosomal ROS.
Bacteria and viruses activate distinct ROS pathways. Plasma
membrane TLRs, especially TLR1, TLR2, and TLR4, and not
those present within endosomes (such as TLR7), sense bacteria
resulting in the recruitment of mitochondria to macrophage
phagosomes and mitochondrial dependent ROS production25.
However, the stimulation of endosomal TLRs failed to augment
mitochondrial ROS25. We conﬁrmed that TLR7 activation with
imiquimod, which caused a signiﬁcant elevation in endosomal
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superoxide production (Supplementary Fig. 3i). We examined the
production of phagosomal ROS in response to the Gram-positive
bacteria Streptococcus pneumoniae (SP) or gram-negative
non-typeable Haemophilus inﬂuenzae (NTHI). Both SP and
NTHI caused ROS production in WT mouse macrophages
(Fig. 4), which was enhanced in SOD3−/− cells (Supplementary
Fig. 2j), but unaffected in TLR7−/− macrophages (Fig. 4). Thus,
endosomal ROS production is not a characteristic of endocytosis
per se, but a “pathogen (cargo)-speciﬁc” response. ROS produced
for antibacterial purposes involves an obligatory role of
mitochondria, which serves as a central hub to promote innate
immune signaling. By contrast, ssRNA viruses do not employ
these antibacterial ROS generating pathways.
Endosomal H2O2 suppresses TLR7 immunity. To establish the
functional importance of endosomal ROS, we assessed the
impact of NOX2 inhibition on the production of cytokines that
are endosome TLR7-dependent and thus relevant to virus
pathogenicity19. We ﬁrst conﬁrmed an endosome- and
TLR7-dependent signal by showing that imiquimod caused a
signiﬁcant elevation in IFN-β, IL-1β, TNF-α, and IL-6 expression
in WT macrophages, but not in TLR7−/− macrophages (Fig. 5a)
or in macrophages treated with baﬁlomycin A (100 nM) (Fig. 5b).
Second, pre-treatment with the NOX2 oxidase inhibitor and
H2O2 scavenger, apocynin (300 μM) signiﬁcantly enhanced
IFN-β, IL-1β, TNF-α, and IL-6 expression in response to
imiquimod, in WT macrophages but not in TLR7−/−
macrophages, indicating that the suppressive effect of NOX2
oxidase-derived ROS on cytokine expression is dependent on
TLR7 (Fig. 5a). In contrast, IFN-β, IL-1β, TNF-α, and IL-6
expression in response to the TLR3 agonist, poly I:C (25 μg/ml),
was suppressed by apocynin pre-treatment (Supplementary
Fig. 6a) whereas increases in these same cytokines triggered by
the TLR9 agonist CpG (10 μg/ml), were unaffected by apocynin
(Supplementary Fig. 6b). We further tested whether NOX2
oxidase inﬂuences TLR7 immunity in vivo. WT and NOX2−/y
mice were treated with a single dose of imiquimod (50 μg per
mouse, intranasally) for measurements of lung IFN-β, IL-1β, IL-6,
and TNF-α after 24 h. This time point was chosen to reﬂect early
phases of RNA infection. There were no discernible alterations in
airway inﬂammation in response to imiquimod (Fig. 5c),
however, imiquimod treatment resulted in elevated levels of
IFN-β, IL-1β, IL-6, and TNF-α in NOX2−/y mice (Fig. 5d).
We sought to establish how endosomal NOX2 oxidase activity
results in the suppression of TLR7-dependent responses and
hypothesized that the parent species superoxide and its
immediate downstream product, H2O2 are culprit mediators.
Inactivation of superoxide by adding exogenous SOD (300 U/ml)
failed to inﬂuence either basal or imiquimod-stimulated
expression of IFN-β, IL-1β, TNF-α, and IL-6, suggesting little
role for superoxide itself in modulating TLR7 responses
(Supplementary Fig. 7). To examine H2O2, we utilized catalase
to inactivate the H2O2 generated within endosomes. We found
that within 30 min, exposure to a FITC-labeled catalase resulted
in co-localization with LysoTracker, conﬁrming internalization
into acidiﬁed endosomal compartments (Fig. 6a). A 1 h “pulse”
exposure to catalase (1000 U/ml) resulted in signiﬁcant elevations
in IFN-β and IL-1β expression after 24 h in WT macrophages,
but not in TLR7−/− macrophages (Fig. 6b). Moreover,
imiquimod-dependent responses were signiﬁcantly increased
in the presence of catalase (Fig. 6c). The catalase-dependent
increase in cytokines was signiﬁcantly suppressed in WT
macrophages treated with Dynasore (Fig. 6d) but unaffected in
TLR2−/− macrophages (Fig. 6e, Supplementary Fig. 8a). The
translocation of TLR7 to endosomes is governed by the actions of
the chaperone protein, UNCB93. Indeed in the absence of
UNCB93 there are substantial signaling defects due to the failure
of the nucleotide-sensing TLRs to reach the endolysosomes,
where they initiate MyD88/TRIF-dependent signaling pathways.
In UNCB93−/− cells, the increase in cytokines to catalase
treatment was signiﬁcantly smaller than that observed in
WT cells (Fig. 6f, Supplementary Fig. 8b). Thus, the suppressive
actions of H2O2 are most likely occurring when TLR7 is located
within the endosomal compartment. Catalase had no effect on
TLR7, TREML4 or NLRP3 expression indicating that H2O2
does not modulate the expression of TLR7, a positive regulator
of TLR7 activity (i.e., TREML426) or NLRP3 that drives
similar anti-viral cytokines to TLR7 (Fig. 6g–j). Therefore the
effect of H2O2 is likely to be post-translational. We then
examined whether endosomal NOX2 oxidase-derived H2O2
inﬂuences TLR7 responses in vivo. We administered catalase
(1000 U per mouse) intranasally to WT mice and showed a three
to four fold increase in lung IFN-β, IL-1β, TNF-α, and IL-6 after
24 h and this occurred prior to overt airway inﬂammation
(Fig. 6k, l).
We questioned whether H2O2 released by endosomal NOX2
oxidase targets cysteine residues on protein domains of TLR7 that
regulate receptor activity and are exposed upon activation within
endosomal compartments27. These include Cys260, Cys263,
Cys270, and Cys273 within the leucine repeat region as well
as two additional cysteines, Cys98 and Cys445 that are unique
to TLR7 (Supplementary Figs. 9 and 10). We performed
site-directed mutagenesis to create a series of TLR7 mutants
including (1) a mutant with all six of these cysteine
residues replaced with alanine, (2) mutants with a dual mutation
of Cys98 and Cys445 (TLR7C98A/C445A), and (3) single mutations
of Cys98 (TLR7C98A) and Cys445 (TLR7C445A). Transfection
of WT TLR7 or TLR7C445A into TLR7−/− macrophages
restored the ability of imiquimod to stimulate cytokine expression
Fig. 2 Co-localization of TLR7 with inﬂuenza A virus, NOX2 and EEA1 is a signaling platform for endosomal ROS generation to inﬂuenza A virus via a TLR7
and PKC-dependent mechanism. a–c Confocal microscopy of mouse primary alveolar macrophages that were untreated or infected with inﬂuenza A virus
HKx31 (MOI of 10) and labeled with antibodies to TLR7 and either a inﬂuenza A virus NP, b NOX2 or c EEA1, and then with 4′,6′-diamidino-2-phenylindole
(DAPI). Quantiﬁcation data from multiple experiments are also shown (n= 5). d Endosomal ROS production in WT and TLR7−/− mouse primary alveolar
macrophages as assessed by Oxyburst (100 μM) ﬂuorescence microscopy in the absence or presence of HKx31 virus and labeled with DAPI (n= 6).
e Immunoﬂuorescence microscopy for assessment of NOX2 and p47phox association. WT and TLR7−/− immortalized bone marrow-derived macrophages
(BMDMs) were untreated or infected with HKx31 virus, (MOI of 10) in the absence or presence of baﬁlomycin A (Baf-A; 100 nM) or dynasore (Dyna; 100
μM), and then labeled with antibodies to NOX2 and p47phox. Also shown is the quantiﬁcation of the results (n= 5). f, g Endosomal ROS production in WT
and NOX2−/y mouse primary alveolar macrophages as assessed by Oxyburst ﬂuorescence microscopy in the absence or presence of f imiquimod (Imiq; 10
μg/ml) and g ssRNA (100 μg/ml) and co-labeled with DAPI. (n= 5). h, i Cytosolic PKC activity as assessed by FRET analysis in WT and TLR7−/− BMDMs.
Cells were either treated with vehicle controls or with baﬁlomycin A (100 nM) or dynasore (10 μM) and then exposed for 25 min to inﬂuenza A virus
(HKx31, MOI of 10) or imiquimod (10 μg/ml) (n= 3). a–g Images are representative of >150 cells analyzed over each experiment. Original magniﬁcation
×100. All data are represented as mean± S.E.M. a, b, c, f and g Student’s unpaired t-test *P< 0.05. d, e, h and i One-way ANOVA followed by Dunnett’s
post hoc test for multiple comparisons. *P< 0.05. Scale bars: 10 µm
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in these cells; however, transfection with the TLR7 containing the
6 mutations, the TLR7C98A/C445A or the TLR7C98A did not
(Fig. 7a). Catalase (1000 U/ml) treatment had little or no effect on
cytokine expression in cells expressing the mutated TLR7,
TLR7C98A/C445A or TLR7C98A whereas it markedly increased
cytokine expression in cells with WT TLR7 or TLR7C445A
(Fig. 7a).
We performed sequence analysis using both multiple sequence
analysis algorithms (i.e., CLUSTAL OMEGA) and pair-wise
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point. Using the multiple sequence analysis we identiﬁed that
Cys98 was unique to TLR7 and fully conserved in vertebrate
TLR7 including from teleosts to man (Fig. 7b, Supplementary
Figs. 9 and 10). Pair-wise sequence alignment showed that Cys98
was the only cysteine residue of the 27 cysteines on TLR7 that
was unique to TLR7 and fully conserved in vertebrates
(Supplementary Table 1). We suggest that H2O2 produced by
endosomal NOX2 oxidase is likely to modify a single and
evolutionary conserved unique cysteine residue i.e., Cys98 located
on the endosomal face of TLR7, resulting in a dampened antiviral
cytokine response. Potentially this signiﬁes Cys98 of TLR7 as a
novel redox sensor that controls immune function during viral
infections. The precise type of molecular modiﬁcation of this
cysteine by H2O2, however, is currently unknown and certainly
warrants further investigation.
NOX2 oxidase dampens antibody production. We examined if
the suppressive effect of endosomal NOX2 oxidase activity on
Type I IFN and IL-1β expression also occurs following inﬂuenza
A virus infection. Firstly, virus triggered translocation of the
transcription factor, IRF-7, to the nucleus of WT BMDMs, but
not TLR7−/− BMDMs, indicating that inﬂuenza A virus activates
TLR7-dependent antiviral signaling in macrophages
(Supplementary Fig. 11). Second, virus elevated IFN-β, IL-1β,
IL-6, and TNF-α expression to a greater extent in NOX2−/y AMs
(Fig. 8a). Third, inﬂuenza A virus (Hkx31; 105 PFU per mouse)
infection in mice in vivo for 24 h resulted in greater increases in
lung IFN-β, IL-1β, IL-6, and TNF-α mRNA (Fig. 8b), as well as
serum (Fig. 8c) and lung IFN-β protein (Fig. 8d) in NOX2−/y
mice. Thus a fully functional NOX2 oxidase suppresses anti-viral
cytokine production triggered by inﬂuenza A virus.
TLR7 is essential for the activation of B-cells and for antibody
production. To test whether NOX2 oxidase suppresses
TLR7-dependent immunity to inﬂuenza A virus in vivo, we used
heat-inactivated, replication-deﬁcient inﬂuenza A virus as a
stimulus, and hence a form of virus expected to mainly trigger
engagement of the TLR7 PRR with very little contribution of RIG-I
and NLRP320. Intranasal inoculation with inactivated virus had no
effect on weight loss over 7-days (Fig. 8e) or airways BALF
inﬂammation (Fig. 8f). NOX2 deletion resulted in a signiﬁcant
elevation in lung levels of IFN-β and IL-1β (Fig. 8g), and in both
serum and BALF levels of IgA, total IgG, IgG1, IgG2b, and IgG3
(Fig. 8h, i). Therefore, activation of endosomal NOX2 oxidase
following inﬂuenza A virus infection results in the suppression of
antiviral cytokines and humoral immunity via the suppression of
antibody production—processes that are required for optimal
clearance of the virus and resistance to re-infection.
Endosomal targeted NOX2 inhibitor. We synthesized an
innovative molecular targeting system, to deliver a speciﬁc NOX2
oxidase inhibitor (i.e., gp91ds-TAT) directly to endosomes, so as
to disrupt the viral signaling platform by abrogating ROS pro-
duction. To do this we generated a tripartite structure
comprising gp91ds-tat conjugated to the membrane anchor
cholestanol via a PEG-linker at the N-terminal region of the
peptide. Similar constructs have been shown previously to
enhance endosome localization for inhibitors of the enzyme beta
secretase28. A Cy5 ﬂuorophore conjugated to cholestanol using
the same PEG linker resulted in cytosolic ﬂuorescence in the
peri-nuclear region and co-localization with EEA1, NOX2 and
inﬂuenza virus NP following viral infection in a dynasore (100
μM)-sensitive manner providing evidence for endocytosis as its
primary mode of cell entry (Fig. 9a–e). Superoxide generation in
macrophages in vitro was suppressed with at least a 10-fold
greater potency by cholestanol-conjugated gp91ds-TAT
(Cgp91ds-TAT) when compared to the unconjugated drug
(Ugp91ds-TAT; Fig. 9f), which is not attributed to enhanced ROS
scavenging properties of the compound (Fig. 9g).
We examined whether Cgp91ds-TAT suppresses disease
severity following inﬂuenza A virus infection in vivo. Daily
intranasal administration of Cgp91ds-TAT (0.02 mg/kg/day)
from 1 day prior, until day 3 post-inﬂuenza A virus infection
resulted in a ~40% reduction in airways inﬂammation (Fig. 9h),
whereas Ugp91ds-TAT had no signiﬁcant effect (Fig. 9h).
Cgp91ds-TAT signiﬁcantly increased lung Type I IFN-β mRNA
levels compared to the control virus group, whereas Ugp91ds-
TAT failed to do so (Fig. 9i). To eliminate the possibility that this
improvement in NOX2 inhibition by cholestanol conjugation of
gp91ds-TAT was attributed to cholestanol-PEG linker per se, we
conjugated the cholestanol PEG-linker to a scrambled gp91ds-
TAT (Sgp91ds-TAT) and examined its effect against inﬂuenza
infection in vivo. Sgp91ds-TAT had no effect on airway
inﬂammation, lung IFN-β mRNA levels and superoxide
production (Supplementary Fig. 12). Increasing the dose of the
Ugp91ds-TAT by 10-fold to 0.2 mg/kg/day signiﬁcantly reduced
the weight loss caused by inﬂuenza A virus at day 3 and almost
abolished airway inﬂammation, as well superoxide production in
BALF inﬂammatory cells, similar to Cgp91ds-TAT at the same
dose (Fig. 9j–l). Strikingly, both Cgp91ds-TAT (0.2 mg/kg/day)
and Ugp91ds-TAT (0.2 mg/kg/day) caused an almost 10,000-fold,
decrease in lung inﬂuenza A viral burden (Fig. 9m). Thus,
suppression of endosome NOX2 oxidase via nasal administration
of gp91ds-TAT results in a substantial reduction in inﬂuenza
A virus pathogenicity. This is an innovative approach for
suppressing NOX2 oxidase activity that occurs within the
endosome compartment. We would like to emphasize that our
custom-made NOX2 inhibitor is unlikely to solely suppress
endosome NOX2. However, our inhibitor is speciﬁcally and
preferentially delivered via the endocytic compartment owing to
the cholestanol conjugation. In support of this, our ﬁndings of
Fig. 9a and b show that cholestanol conjugation results in a drug
delivery system that promotes endosome delivery i.e our drug
displayed a strong degree of co-location with EEA1+ endosomes
that was abolished by dynasore pretreatment. This delivery
system brings a NOX2 inhibitor to the predominant site of action
that relates to virus infection (see Fig. 9d showing strong
co-location of viral nucleoprotein and our NOX2 inhibitor).
Fig. 3 Endosomal ROS production to ssRNA and DNA viruses are via TLR7 and TLR9-dependent mechanisms, respectively. a Endosomal ROS production in
WT and TLR7−/− bone marrow-derived macrophages as assessed by OxyBURST (100 μM) ﬂuorescence microscopy in the absence or presence of
inﬂuenza A virus (HKx31 virus), rhinovirus (rhino), respiratory synctitial virus (RSV), human parainﬂuenza virus (PIV), human metapneumovirus (HMPV),
sendai virus, dengue virus, human immunodeﬁciency virus (HIV), mumps virus (MuV), Newcastle disease virus (NDV), rotavirus (UK and bovine strains),
herpes simplex virus 2 (HSV-2), and vaccinia virus and labeled with 4′,6′-diamidino-2-phenylindole (DAPI). Also shown is the quantiﬁcation of the
results (n= 5). b Endosomal ROS production in WT and TLR9−/− mouse primary alveolar macrophages as assessed by OxyBURST ﬂuorescence
microscopy in the absence or presence of HKx31 virus, rhinovirus, sendai virus, dengue virus, and herpes simplex virus 2 (HSV-2) and labeled with DAPI
(n= 5). a and b Images are representative of >150 cells analyzed over each experiment. Original magniﬁcation ×100. All data are represented as mean± S.E.M.
One-way ANOVA followed by Dunnett’s post hoc test for multiple comparisons. #P< 0.05 compared to WT control. *P< 0.05 comparisons indicated by
horizontal bars. Scale bars: 10 µm
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We speculate that following internalization into the
endosome the drug is most likely on the luminal face of
the endosome membrane and due to the TAT portion can
penetrate the membrane and suppress NOX2 activity. The drug
might still be able to diffuse towards other sites or locations of
NOX2, however, we believe the immediate and primary site of
action will be NOX2 activity at the endosome, given that the drug
appears to be selectively delivered via the endocytic pathway.
Discussion
We have accumulated evidence that virus entry into endosomal
compartments triggers a NOX2 oxidase- dependent production of
ROS in endosomes. However, some ROS may have possibly been
generated in sites outside of the endosome, which may have then
diffused into the endosomes. As such the site of ROS generation
and site of detection in some instances might be
distinct. We suggest that the major contributor to endosomal
concentrations of superoxide will be superoxide generated
directly in this compartment. Superoxide is the primary product
of NOX2 and it will only be generated within the endosome
compartment owing to the topology of the NOX2 and the
unidirectional transfer of electrons through this catalytic subunit.
In keeping with this, it is well regarded that superoxide does not
travel far from its site of generation due to its negative charge. By
contrast to superoxide, H2O2 has some capacity to permeate
membranes and diffuse, and as such, it can be envisaged that
some endosome H2O2 might have been generated elsewhere by
NOX2 expressed in other sites of the cell such as the plasma
membrane. However for several lines of evidence we suggest that
it is very likely that little remotely generated H2O2 is ﬁnding its
way into the endosome compartment. First we demonstrate that
PKC activation following virus infection, which is critical for
NOX2 activation, is signiﬁcantly impaired if: (1) the virus is
prevented from entering cells (Fig. 2h, i); (2) endosome
acidiﬁcation is blocked by Baﬁlomycin A (Fig. 2h, i) or (3) if
TLR7 is absent (i.e., TLR7−/− macrophages are used). Therefore,
endosomal NOX2 derived ROS generation occurs only after virus
has entered endosomes and activates endosome-speciﬁc path-
ways, lending further credence to endosome NOX2 as the
predominant site of H2O2 generation. Second, elegant studies
addressing spatialtemporal aspects of H2O2 diffusion clearly
demonstrate that H2O2 diffusion in the cytoplasm is strongly
limited, but is instead localized to near the sites of its
generation29, providing evidence that endosome H2O2 is unlikely
to have been generated at a remote site.
Here we demonstrate that endosomal ROS are essential
negative regulators of a fundamental molecular mechanism of viral
pathogenicity that impacts on antiviral immunity and the capacity
of the host to ﬁght and clear viral infections. Importantly, this
effect is conserved, regardless of viral classiﬁcation, for all viruses
that enter cells via the endocytic pathway, and is TLR7 dependent.
This provides a potential target for antiviral therapy for a range of
viruses that cause signiﬁcant morbidity and mortality worldwide.
Previous work has demonstrated that a deﬁciency in the phagocyte
NADPH oxidase can result in exacerbated inﬂammation and
necrosis in response to fungal components including β-glucans
that activate TLR2 and dectin-130. Our study is not a universal
mechanism that deﬁnes how NOX2 oxidase might be regulating
inﬂammation to fungi and other pathogens but certainly provides
strong mechanistic insight into ROS-dependent regulation of
antiviral immunity.
Intriguingly, our study raises a broader paradox: Why does a
mammalian cell generate ROS that may ultimately cause harm (i.e.,
by promoting viral pathogenicity)? We hypothesize that suppres-
sion of TLR7 activation by endosomal NOX2 is a hitherto unrec-
ognized mechanism that has evolved to inhibit an
inﬂammatory response against self-RNA/antigens and the devel-
opment of autoimmunity, but which in a very similar manner
results in a host response to viral RNA that inadvertently exacer-
bates viral pathogenicity. Realizing the delicate balance between
viral clearance and the induction of an autoimmune response, the
current data suggest the potential to employ short term suppression
of endosomal ROS as a means of reducing viral pathogenicity
without causing long term problems with autoimmunity.
Methods
Viruses. The inﬂuenza A virus vaccine strains HKx31 (H3N2) and BJx109 (H3N2)



























































Fig. 4 Bacteria-induced ROS production is distinct from virus-dependent ROS mechanisms. a Phagosomal superoxide production to Haemophilus inﬂuenzae
and Streptococcus pneumoniae as assessed by OxyBURST (100 μM) ﬂuorescence microscopy in WT and TLR7−/− immortalized bone marrow derived
macrophages. Images are representative of >150 cells analyzed over each experiment. Original magniﬁcation ×100. b Is the quantiﬁcation of the results
(n= 5). All data are represented as mean± S.E.M. One-way ANOVA followed by Dunnett’s post hoc test for multiple comparisons. *P< 0.05 compared to
WT control. Scale bar: 10 µm
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University, CSIRO) and A/Prof. Patrick Reading (Department of Immunology and
Microbiology, University of Melbourne, The Peter Doherty Institute for Infection
and Immunity). Human strains of inﬂuenza A virus, including seasonal H3N2
(A/New York/55/2004, A/Brisbane/9/2007), seasonal H1N1 (A/Brazil/11/1978,
A/New Caledonia/20/1999, A/Solomon Islands/3/2006), A(H1N1)pdm09 strains
(A/California/7/2009, A/Auckland/1/2009), rhinovirus (RV16 strain), respiratory
synctitial virus (strain A2), human parainﬂuenza virus type-3 (C243), human
metapneumovirus (strain CAN97-83), mumps virus (strain Enders), and Newcastle
disease virus (strain V4) were provided by A/Prof Patrick Reading. Additional
viruses were provided by the following people: dengue virus serotype 2 (Vietnam
2005 isolate, Associate Prof Elizabeth McGraw; Monash University); rotavirus
(Rhesus and UK strains, A/Prof Barbara Coulson, Department of Microbiology and
Immunology, The Peter Doherty Institute for Infection and Immunity); sendai
virus (Cantell strain, Dr Ashley Mansell from Hudson Institute of Medical
Research, Monash University), herpes simplex virus type-2 (strain 186; Dr Niahm
Mangan, Hudson Institute of Medical Research, Monash University), vaccinia virus
(Western Reserve strain, WR NIH-TC; A/Prof. David Tscharke, Australia National
University), and HIV (NL4-3(AD8)-EGFP strain, Prof. Sharon Lewin, The Peter
Doherty Institute for Infection and Immunity, The University of Melbourne). The
viruses were provided in phosphate buffered saline (PBS, Cat # D8537, Sigma,
USA) and stored at −80 ºC until used. On the day of use, virus was thawed quickly
and incubated at 37 ºC prior to infection. Where indicated, HKx31 virus was
inactivated by heat (56 ºC) for 30 min or UV light (30 min).
Bacteria. S. pneumoniae EF3030 (capsular type 19 F) was used as the parent
S. pneumoniae strain in all experiments (provided by Dr. Odilia Wijburg,
University of Melbourne, Australia). S. pneumoniae EF3030 is a clinical isolate that
is frequently used as a model of human carriage as it typically colonizes the
nasopharynx in the absence of bacteremia. For infection experiments, pneumococci
were grown statically at 37 °C in Todd-Hewitt broth, supplemented with 0.5% yeast
extract, to an optical density (600 nm) of 0.4–0.45. Cultures were placed on wet
ice for 5 min and frozen in 8% (v/v) glycerol at −70 °C. Live bacterial counts were
conﬁrmed prior to each experiment. A deﬁned strain of non-typeable H. inﬂuenzae
(NTHi; MU/MMC-1) was previously typed and sequenced and demonstrated to be
NTHi, as we have previously shown31.
Conjugation of NOX2 oxidase inhibitors. Preparation of gp91 ds-tat
(YGRKK-RRQRR-RCSTR-IRRQL-NH2) was carried out by standard Fmoc
solid-phase peptide synthesis (SPPS) on Fmoc-PAL-PEG-PS resin (Life
Technologies, USA, loading 0.17 mmol/g). Fmoc deprotection reactions were
carried out using 20% v/v piperidine in N,N-dimethylformamide (DMF).
Coupling reactions were carried out using Fmoc-protected amino acids with
O-(6-chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexaﬂuoropho-
sphate (HCTU) as coupling agent and N,N-diisopropylethylamine (DIPEA) as
activating agent. Reactions were monitored using the 2,4,6-trinitrobenzenesulfonic





































































































































































































































































































































































































































































































































































































































Fig. 5 Endosomal NOX2 oxidase suppresses cytokine expression in response to TLR7 activation in vitro and in vivo. a, b WT and TLR7−/− immortalized
bone marrow-derived macrophages (BMDMs) were untreated or treated with imiquimod (Imiq; 10 μg/ml) in the absence or presence of a apocynin
(Apo; 300 μM) or b baﬁlomycin A (Baf-A; 100 nM), and IFN-β, IL-1β, TNF-α and IL-6 mRNA expression determined by QPCR after 24 h (n= 6). c, d WT
and NOX2−/y mice were administered with imiquimod (50 μg per mouse, intranasal) and c total airway inﬂammation quantiﬁed by bronchoalveolar lavage
ﬂuid analysis and d cytokine expression assessed 24 h later (n= 5). a, b, d Responses are relative to GAPDH and then expressed as a fold-change above
WT controls. a–d Data are represented as mean± S.E.M. a, b and d Kruskal–Wallis test with Dunn’s post hoc for multiple comparisons. c One-way
ANOVA followed by Dunnett’s post hoc test for multiple comparisons. Statistical signiﬁcance was accepted when P< 0.05. *P< 0.05; **P< 0.01
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sequence of deprotection and coupling reactions was carried out manually for all
20 amino acid residues using the appropriate Fmoc- and side-chain protected
amino acids. After a ﬁnal de-protection step, a small portion of the peptide
was cleaved from resin using triﬂuoroacetic acid (TFA)/triisopropylsilane
(TIPS)/1,2-ethanedithiol (EDT)/water (92.5:2.5:2.5:2.5) for 4 h, during which time
the side-chain protecting groups were simultaneously removed. The crude peptide
was then puriﬁed by reverse-phase high-pressure liquid chromatography using a
Phenomenex Luna 5 C8 (2) 100 Å AXIA column (10 Å, 250 × 21.2 mm) with 0.1%
TFA/water and 0.1% TFA/ACN as the buffer solutions. The puriﬁed gp91 ds-tat
peptide was conﬁrmed as having the correct molecular weight by ESI-MS analysis:
calcd. for C109H207N52O25S [M + 5H+] m/z 535.3, obs. m/z 535.7; calcd. for
C109H208N52O25S [M + 6H+] m/z 446.3, obs. m/z 446.6; calcd. for C109H209N52O25S
[M + 7H+] m/z 382.7, obs. m/z 382.9.
Preparation of cholestanol-conjugated gp91 ds-tat (cgp91 ds-tat; Ac-Asp
(OChol)-PEG4-PEG3-PEG4-gp91-NH2) was carried out by manual SPPS from
resin-bound gp91 ds-tat (as described above), using Fmoc-PEG4-OH,
Fmoc-PEG3-OH, Fmoc-PEG4-OH and Fmoc-Asp(OChol)-OH as the amino acids.
After the ﬁnal deprotection step, the N-terminus was capped using a mixture of
acetic anhydride and DIPEA in DMF and the peptide construct was cleaved from
resin using TFA/TIPS/EDT/water (92.5:2.5:2.5:2.5). The crude peptide was puriﬁed
as described previously to give cgp91 ds-tat: calcd. for C173H319N56O43S [M + 5H+]
m/z 780.3, obs. m/z 780.6; calcd. for C173H320N56O43S [M + 6H+] m/z 650.4, obs.
m/z 650.7; calcd. for C173H321N56O43S [M + 7H+] m/z 557.6, obs. m/z 558.0.
Preparation of ethyl ester-conjugated gp91 ds-tat (egp91 ds-tat; Ac-Asp(OEt)-
PEG4-PEG3-PEG4-gp91-NH2) was carried out in the same way as for cgp91 ds-tat,
except for replacement of Fmoc-Asp(OChol)-OH with Fmoc-Asp(OEt)-OH in the
ﬁnal coupling step: calcd. for C148H277N56O43S [M + 5H+] m/z 711.8, obs. m/z
712.1; calcd. for C148H278N56O43S [M + 6H+] m/z 593.3, obs. m/z 593.7; calcd. for
C148H279N56O43S [M + 7H+] m/z 508.7, obs. m/z 509.0.
Preparation of the 18 amino acid scrambled gp91 ds-tat (Sgp91 ds-tat; Ac-Asp
(OChol)-PEG4-PEG3-PEG4-RKK-RRQRR-RCLRI-TRQSR-NH2) peptide was
carried out by manual SPPS as described above for unscrambled gp91 ds-tat. The
resin-bound sgp91 ds-tat was then conjugated to cholestanol via a PEG linker using
the same method described above for unscrambled cgp91 ds-tat. The crude peptide
was puriﬁed in the same way to give cgp91 ds-tat: calcd. for C162H307N54O40S [M +
5H+] m/z 736.3, obs. m/z 736.5; calcd. for C162H308N54O40S [M + 6H+] m/z 613.7,
obs. m/z 614.0; calcd. for C162H309N54O40S [M + 7H+] m/z 526.2, obs. m/z 526.3
Animal ethics statement. The mouse experiments described in this manuscript























































































































































































































































































































































































































































































































































































































































Fig. 6 Endosomal NOX2 oxidase-derived hydrogen peroxide (H2O2) inhibits cytokine expression in response to TLR7 activation in vitro and in vivo.
a WT mouse primary alveolar macrophages were either left untreated or treated with FITC-labeled catalase for 5 min prior to infection with HKx31 virus
(MOI of 10). Cells were labeled for Lysotracker (50 nM) and colocalization of Lysotracker and FITC catalase assessed by confocal microscopy. Images are
representative of >100 cells analyzed over each experiment. Original magniﬁcation ×100 (n= 3). b WT and TLR7−/− immortalized bone marrow-derived
macrophages (BMDMs) were left untreated or treated for 1 h with catalase (1000 U/ml) and IFN-β and IL-1β, mRNA expression determined by QPCR after
24 h (n= 7). cWT BMDMs were left untreated or treated for 1 h with imiquimod (Imiq) in the absence or presence of catalase (1000 U/ml), IFN-β and IL-
1β, mRNA expression assessed 24 h later by QPCR (n= 6). dWT BMDMs were treated for 30min with either DMSO (0.1%) or dynasore (Dyna; 100 μM)
and then with catalase (1000 U/ml) for 1 h. Cytokine mRNA expression determined by QPCR after 24 h (n= 6). e WT and TLR2−/− immortalized BMDMs
were treated with catalase (1000 U/ml) for 1 h and cytokine mRNA expression determined by QPCR after 24 h (n= 6). fWT and UNCB93−/− immortalized
BMDMs were treated with catalase (1000 U/ml) for 1 h and cytokine mRNA expression determined by QPCR after 24 h (n= 6). g–i WT BMDMs were
treated for 1 h with either catalase or imiquimod (10 μg/ml) and g TLR7, h NLRP3 or i TREML4 mRNA expression determined by QPCR after 24 h (n= 6).
jMice were intranasally treated with catalase (1000 U per mouse) and then lung expression of TREML4 was determined by QPCR (n= 5). k and l Catalase
(1000 U per mouse, intranasal) was administered to WT mice and k total BALF airway inﬂammation and l lung cytokine expression assessed 24 h later
(n= 5). b–j and l Responses are relative to GAPDH and then expressed as a fold-change above WT controls. b–h and l Kruskal–Wallis test with Dunn’s post
hoc for multiple comparisons. i and j Mann–Whitney Wilcoxon test. All data are represented as mean± S.E.M. Statistical signiﬁcance was taken when the
P< 0.05. *P< 0.05. Scale bar: 10 µm
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University of Melbourne and Monash University and conducted in compliance
with the guidelines of the National Health and Medical Research Council
(NHMRC) of Australia on animal experimentation.
In vivo infection with inﬂuenza A virus and drug treatments. Aged matched
(6–12 weeks) littermate male naïve WT control and NOX2−/y mice (also known as
gp91phox−/− mice were originally generated in the laboratory of Prof Mary
Dinauer32) were anaesthetized by penthrane inhalation and infected intranasally
(i.n.) 1 × 104 or 1 × 105 plaque forming units (PFU) of Hk-x31 in a 35 µl volume,
diluted in PBS. Mice were euthanised at Day 1, 3 or 7 following inﬂuenza
infections. In some experiments, anaesthetized mice were treated via intranasal
delivery with either dimethyl sulphoxide (DMSO, control; Sigma), unconjugated
gp91dstat (0.02 mg/kg, 0.2 mg/kg), cholestanol conjugated-gp91dstat (0.02 mg/kg,
0.2 mg/kg) or cholestanol conjugated-scrambled gp91ds-TAT (0.02 mg/kg) one day
prior to infection with Hk-x31 and everyday thereafter for 3 days. In additional
experiments, anaesthetized mice were treated with imiquimod (50 μg per mouse, i.
n.) or catalase (1000 U per mouse, i.n.) and then euthanised for analysis at Day 1.
Airways inﬂammation and differential cell counting. Mice were killed by an
intraperitoneal (i.p.) injection of ketamine/xylazene (100 mg/kg) mixture. An
incision was made from the lower jaw to the top of the rib cage, where the salivary
glands were separated to expose the surface of the trachea. The layer of smooth
muscle on the trachea was removed, allowing a small incision to be made near the
top of the trachea. A sheathed 21-Gauge needle was inserted to the lumen and
300–400 µl of PBS was lavaged repeatedly (four times). The total number cells in







































































































































































































































































































































































Human 95 D F R C N C V 101
Mouse 95 D L R C N C V 101
Rat 95 D L R C N C V 101
Chicken 103 D L R C N C V 109
Frog 101 D F R C N C V 107
Pig 95 D F R C N C I 95
Salmon 103 D F R C N C I 106
Zebrafish 90 D L R C N C V 96
Fig. 7 C98 on TLR7 regulates activity of the receptor and is a target for endosomal H2O2. a TLR7−/− BMDMs were transfected with empty vector, WT TLR7
or with either TLR7 with cysteines 98, 260, 263, 270, 273, and 445 mutated to alanine (TLR7 6 mut), TLR7 with cysteines 98 and 445 mutated to alanine
(TLR7C98A/445 A) or with TLR7 with cysteines 445 (TLR7C445A) or 98 (TLR7C98A) mutated to alanine. After 48 h, cells were left untreated or treated
for 1 h with either catalase (1000 U/ml) or imiquimod (Imiq, 10 μg/ml) and cytokine expression assessed 24 h later (n= 6). Responses are relative to
GAPDH and then expressed as a fold-change above TLR7−/− controls. Data are represented as mean± S.E.M. One-way ANOVA followed by Dunnett’s
post hoc test for multiple comparisons. Statistical signiﬁcance was accepted when P< 0.05. *P< 0.05. (NS) Denotes not signiﬁcant. b Multiple sequence
alignment with CLUSTAL OMEGA showing across species conservation of Cys 98 on TLR7
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USA) and viable cells were evaluated using the Countess automated cell counter
(Invitrogen, Cat # C10227). Differential cell analysis was prepared from BALF
(5 × 104 cells) that were centrifuged at 3 × g for 5 min on the Cytospin 3 (Shandon,
UK). Following this, slides were ﬁxed in 100% propanol for 1 min and allowed
to dry overnight. Finally, samples were stained with Rapid I Aqueous Red StainTM
(AMBER Scientiﬁc, Australia) and Rapid II Blue StainTM (AMBER Scientiﬁc,
Australia) for 10 min, then submerged in 70% ethanol and absolute ethanol twice
before being placed into xylene for 5 min (two times). Samples were then mounted
in DPX mounting medium (Labchem, NSW, Australia) and coverslips were
ﬁrmly placed on top. 500 cells per sample from random ﬁelds were differentiated
into macrophages, neutrophils, eosinophils and lymphocytes by standard
morphological criteria. Data are represented as total cell numbers that was
calculated by the respective cell type multiplied by the total live cell numbers and as















































































































































































































































































































































































































































































































































































































































































































































Fig. 8 Inhibition of NOX2 oxidase increases expression of Type I IFN and IL-1β, and antibody production to inﬂuenza A virus infection. a Alveolar
macrophages from WT and Nox2−/y mice were either left untreated (naïve) or infected with HKx31 inﬂuenza A virus (MOI of 10) for analysis of IFN-β,
IL-1β, TNF-α, and IL-6 mRNA expression by QPCR after 24 h (n= 8). b, c WT and Nox2−/y mice were infected with live HKx31 inﬂuenza A virus (1 × 105
PFU per mouse) and b cytokine mRNA expression and IFN-β protein expression in c BALF or d serum were assessed 3 days later (n= 5). e–iWT and Nox2
−/y mice were infected with inactivated HKx31 inﬂuenza A virus (equivalent to 1 × 104 PFU per mouse) for measurements at day 7 of: e body weight;
f airway inﬂammation and differential cell counts (i.e., macrophages, neutrophils, and lymphocytes); g cytokine expression in whole lung (responses
are shown as fold change relative to GAPDH) and h serum and i BALF antibody levels (n= 6). Data are shown as mean± SE. a Kruskal–Wallis test
with Dunn’s post hoc for multiple comparisons. b–i Unpaired t-test; statistical signiﬁcance taken when the P< 0.05. *P< 0.05. **P< 0.01
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Cell culture and primary cell isolation. Human AMs were obtained from subjects
undergoing a bronchoscopy at Monash Medical Centre, Monash University to
investigate underlying lung disease with approval from the ethics committee of
Southern Health/Monash Medical Centre. Written consent was obtained from all
subjects. The bronchoscope was wedged in the right middle lobe and 25–50 ml of
saline was washed into the airway then aspirated. Cells were washed twice with PBS
before being suspended in culture medium (Roswell Park Memorial Institute
(RPMI, Life Technologies, Cat # 21870-076) with 10% FCS with 100 U/ml peni-
cillin and 100 μg/ml streptomycin) for ~24 h before use.
AMs were isolated by lung lavage from age-matched (6–12 weeks) male
C57Bl/6 J (WT), NOX2−/y, NOX4−/− (provided by Dr Hitesh Peshavariya, Centre
for Eye Research, The University of Melbourne, Australia), TLR7−/− (provided by
Prof Phil Hansbro, School of Biomedical Sciences and Pharmacy, Faculty of Health
and Medicine, The University of Newcastle, and Hunter Medical research Institute,
New South Wales, Australia), TLR9−/− (provided by Prof. Karlheinz Peter (Baker
IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia)) or SOD3−/− mice
(provided by A/Prof Steven Bozinovski, School of Health and Biomedical Sciences,
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the rib cage was made and the larynx was separated to expose the top of the
trachea. The layer of smooth muscle covering the trachea was removed, a small
incision made and a sheathed 21-Gauge needle was inserted into the lumen.
The lungs were repeatedly (three times) lavaged with 300–400 µl of PBS. Cell
suspensions were spun down by centrifugation (200 × g at 4 °C for 5 min).
Supernatant was removed, then cells were re-suspended in 1 ml of sterile PBS and
counted using the Countess automated cell counter (Invitrogen, Cat # C10227).
Cells were then seeded into 24-well plates (1 × 105 cells per well) for
immunocytochemistry and ﬂuorescence microscopy, as stated below.
The immortalized cell line RAW 264.7 cells (ATCC TIB-71) and immortalized
BMDMs (courtesy of Dr Ashley Mansell of the Hudson Institute of Medical
Research Monash University and Prof Eicke Latz of the Institute of Innate
Immunity, University of Bonn, Germany) were maintained in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM: Sigma) supplemented with L-glutamine,
glucose (4500 mg/l), sodium pyruvate (110 mg/l), and fetal bovine serum
(FBS; 10%). The TLR2−/−, TLR3−/−, TLR4−/−, TLR7−/−, TRIF−/−, RIG-I−/−,
MyD88−/−, NLRP3−/−, and UNC93B1−/− immortalized BMDMs (provided by
Dr. Ashley Mansell, Dr Michael Gantier and Prof. Eicke Latz) were maintained in
RPMI medium supplemented with glucose (4500 mg/l), non essential amino acids,
sodium pyruvate, streptomycin and FBS (10%) and DMEM (20%) (containing all
supplements, as stated above). All cells were kept at 37 °C with a humidiﬁed
mixture of 5% CO2 and 95% air. The medium was changed two to three times a
week, cells were sub-cultured by scraping when ~80–90% conﬂuent, and counted
using the Countess automated cell counter.
Confocal ﬂuorescence microscopy. Cells were seeded onto glass cover slips in
24-well plates, and allowed to adhere for 24 h in DMEM. Cells were then incubated
in the absence or presence of HKx31 inﬂuenza A virus (MOI 0.1, 1 or 10) in
serum-free medium at varying time points (5, 15, 30 min, and 1 h). In some cases,
cells were pretreated for 30 min prior to infection with Dynasore (100 μM) or the
vehicle for Dynasore, DMSO (0.1%). Next, the cells were washed with PBS (0.01 M)
and ﬁxed with 4% paraformaldehyde (PFA) for 15 min. Cells were treated for 10
min with PBS-containing Triton X-100 (0.25%) and then washed three times over
15 min with PBS. The samples were then incubated with 10% goat serum-
containing PBS for 2 h and/or mouse on mouse IgG blocking reagent (Cat #
MKB-2213, Vector Laboratories). This was followed by the addition of a primary
antibody for nucleoprotein (1:1000) to localize inﬂuenza A virus, puriﬁed mouse
anti-NOX2 (1:500) to localize NOX2, rabbit anti-TLR7 (1:1000) to localize TLR7,
or mouse anti-early endosome antigen 1 (EEA1: 1000) to localize early endosomes
for 24 h at 4 °C. In some experiments, combinations of antibodies were used at the
indicated concentrations to determine protein co-localization. Cells were washed
three times over 30 min with PBS (0.01M). Following the washes, a secondary
antibody goat anti-rabbit alexa 594 (1:1000), goat anti rabbit red 647 (1:500,
1:1000) and/or biotinylated anti-mouse IgG was added to appropriate wells in
the dark for 2 h. Finally, the cells were washed three times over 30 min with PBS
(0.01 M); and where appropriate (mouse primary and secondary anti Fluroscein
Avidin DCS was applied for 5 min). Cover slips were mounted onto microscope
slides with 10–20 µl of diamidino-2-phenylindole (DAPI) for 3 min. Slides were
viewed and photographed on a Nikon upright inverted confocal ﬂuorescence
microscope (Nikon D-eclipse C1). All immunohistochemistry was assessed by two
observers blinded as to the treatment groups throughout the analysis process and
all of the appropriate controls were performed, in that all combinations of primary
and secondary antibodies were used to ensure no cross reactivity occurred.
We veriﬁed the speciﬁcity of both the TLR7 and NOX2 antibodies by examining
the degree of staining in AMs taken from WT, TLR7−/− and NOX2−/− mice,
respectively. There was no staining for TLR7 in the TLR7−/−macrophages (Fig. 2c).
Similarly with the NOX2 antibody we observed no staining in AMs of NOX2−/y
mice compared to the WT cells (Supplementary Fig. 1d). Further evidence for the
speciﬁcity of this NOX2 antibody can be found in Judkins et al.33.
Endosomal ROS production. Human AMs; WT, TLR7−/−, TLR2−/−, TLR3−/−,
TLR4−/−, TRIF−/−, MyD88−/−, RIG-I−/− and NLRP3−/− BMDMs; mouse primary
WT, NOX2−/y, NOX4−/−, TLR7−/−, TLR9−/− or SOD3−/− AMs and RAW264.7 cells
were seeded (1 × 105 cells per well) onto glass coverslips in 24-well plates allowing
the cells to adhere for 24 h in DMEM or RPMI medium before being pretreated
with OxyBURST Green H2HFF (100 μM) and/or LysoTracker Deep Red (50 nM)
for 5 min. This was followed by incubation with PBS (control group; 0.01M),
imiquimod (10 µg/ml), single stranded RNA (ssRNA; 100 μM), or infected with
either H3N2 inﬂuenza viruses (A/New York/55/2004, A/Brisbane/9/2007),
seasonal H1N1 inﬂuenza A viruses (A/Brazil/11/1978, A/New Caledonia/20/1999,
A/Solomon Islands/3/2006), A(H1N1)pdm inﬂuenza A viruses (A/California/7/
2009, A/Auckland/1/2009), or with re-assortant vaccine strains HKx31 (MOI
0.1–10) or BJx109 (MOI 10) in serum-free medium at varying time points (5, 15,
30 min, and 1 h). Other wells were infected with dengue virus (MOI 10), Sendai
virus (40 HAU/ml), human parainﬂuenza virus (MOI 10), human metapneumo-
virus (MOI 10), rhinovirus (MOI 10), respiratory syncytial virus (MOI 10), HIV
(MOI 10), Newcastle disease virus (MOI 10), mumps virus (MOI 10), rhesus or UK
rotaviruses (each at MOI 10) or herpes simplex virus-2 (MOI 10) under similar
conditions. In some cases, cells were pretreated with SOD (300 U/ml), apocynin
(300 μM), gp91dstat (50 μM) or baﬁlomycin A (100 nM), for 30 min prior to
infection. Next, the cells were washed with PBS (0.01 M) and ﬁxed with 4% PFA for
15 min. After ﬁxation, cells were then washed three times with PBS over 30 min.
Cover slips were then mounted onto microscope slides with 10–20 µl of DAPI for 3
min, then analyzed and photographed on an Nikon upright confocal ﬂuorescence
microscope (Nikon D-eclipse C1).
NOX2 oxidase assembly. To measure NOX2 oxidase activity we assessed
p47phox and NOX2 assembly using confocal ﬂuorescence microscopy. Control and
HKx31 virus-infected WT and TLR7−/− AMs were processed as indicated above
under “confocal ﬂuorescence microscopy”. In additional experiments, WT cells
were treated with Dynasore (100 μM) or baﬁlomycin A (100 nM) for 30 min prior
to virus infection. After exposing samples with 10% goat serum-containing PBS for
2 h, the rabbit anti-p47phox antibody (1:1000) and the mouse anti-NOX2 antibody
(1:500) were added followed by addition of appropriate secondary antibodies, as
speciﬁed above.
L-O12-enhanced chemiluminescence. ROS production was quantiﬁed using
L-O12-enhanced chemiluminescence. RAW264.7 cells and primary mouse AMs
were seeded into a 96-well OptiView plate (5 × 104 cells per well). RAW264.7 cells
were either treated with DMSO (control, appropriate concentration), unconjugated
gp91dstat (100 nM–30 μM), cholestanol-conjugated gp91dstat (100 nM–30 μM)
or ethyl-conjugated gp91dstat (100 nM–30 μM) for 1 h. BALF was collected from
mice treated with DMSO (control), unconjugated gp91dstat (0.02 mg/kg,
0.2 mg/kg), cholestanol conjugated-gp91dstat (0.02 mg/kg, 0.2 mg/kg) and/or
infected with Hk-x31 inﬂuenza A virus (1×105 PFUs). Cells were then washed of
media with 37 °C Krebs-HEPES buffer, then exposed to a Krebs-HEPES buffer
containing L-O12 (10−4 mol/l) in the absence (i.e., basal ROS production) or
presence (stimulated ROS production) of the PKC and NADPH oxidase activator
phorbol dibutyrate (PDB; 10−6 mol/l). The same treatments were performed
in blank wells (i.e., with no cells), which served as controls for background
luminescence. All treatment groups were performed in triplicates. Photon emission
[relative light units (RLU)/s] was detected using the Chameleon luminescence
detector (Hidex, model 425105, Finland) and recorded from each well for 1 s over
60 cycles. Individual data points for each group were derived from the average
values of the three replicates minus the respective blank controls. Data are
represented as a % of the control in the dose-response curves or as raw values
(ex vivo experiments).
Fig. 9 Endosome targeted delivery of a NOX2 oxidase inhibitor protects mice following inﬂuenza A virus infection in vivo. a–e Alveolar macrophages from
WT mice were treated with the Cy5 cholestanol-PEG linker ﬂuorophore (Cy5-chol; 100 nM) for 30min and infected with HKx31 inﬂuenza A virus (MOI of
10). Cells were then counter labeled with antibodies to either: a and b EEA1, c NOX2 or d inﬂuenza A nucleoprotein (NP). All cells were then stained with
4′,6′-diamidino-2-phenylindole (DAPI) and imaged with confocal microscopy. b Cells were pretreated with dynasore (100 μM) for 30min prior to
exposure to Cy5-cholestanol. e Quantiﬁcation of data from (a–d, n= 5). f RAW 264.7 macrophages were either untreated or treated with various
concentrations of cholestanol-conjugated gp91ds-TAT (Cgp91), ethyl conjugated gp91ds-TAT (Egp91) or unconjugated gp91ds-TAT (Ugp91) for 30min
prior to quantifying ROS production by L-O12 (100 μM)-enhanced chemiluminescence (n= 7). g Superoxide production via the xanthine/xanthine oxidase
cell-free assay in the absence or presence of Ugp91ds-TAT, (1 μM) or Cgp91ds-TAT (1 μM) (n= 6). h, i Ugp91ds-TAT (0.02mg/kg/day) or Cgp91ds-TAT
(0.02mg/kg/day) were delivered intranasally to WT mice once daily for 4 days. At 24 h after the ﬁrst dose of inhibitor, mice were either treated with
saline or infected with HKx31 inﬂuenza A virus (1 × 105 PFU per mouse). Mice were culled at day 3 post-infection and h airway inﬂammation was assessed
by BALF cell counts and i lung IFN-β mRNA was determined by QPCR (n= 7). (NS) denotes not signiﬁcant. j–mMice were subjected to the NOX2 inhibitor
treatment regime and virus infection protocol as in h except NOX2 inhibitors were delivered at a dose of 0.2 mg/kg/day (n= 7). Analysis of j airway
inﬂammation by BALF counts, k body weight (% weight change from the value measured at Day -1), l ROS production by BALF inﬂammatory cells with L-
O12 enhanced chemiluminescence and m viral mRNA by QPCR. Data are represented as mean± S.E.M. e Unpaired t-test; statistical signiﬁcance taken
when the P< 0.05. f, g, h, j, k, l One-way ANOVA followed by Dunnett’s post hoc test for multiple comparisons. i and m Kruskal–Wallis test with Dunn’s
post hoc for multiple comparisons. Statistical signiﬁcance was accepted when P< 0.05. *P< 0.05; **P< 0.01. Scale bars: 10 µm
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To test whether the unconjugated or cholestanol conjugated gp91dstat exhibited
ROS scavenging properties, the xanthine oxidase cell free assay was used. Brieﬂy,
Krebs-HEPES buffer containing L-012 (100 μM) was added into a 96-well Optiview
plate. Following this, 0.1% DMSO, unconjugated gp91dstat (Ugp91ds-TAT, 1 μM)
or cholestanol-conjugated gp91ds-TAT (1 μM) were added in combination with
Xanthine (100 μM). Immediately after xanthine oxidase (0.03 U/ml) was added,
photon emission [relative light units (RLU)/s] was detected using the Chameleon
luminescence detector (Hidex, model 425105, Finland) and recorded from each
well for 1 s over 60 cycles. Individual data points for each group were derived from
the average values of the three replicates minus the respective blank controls. Data
are represented as raw values.
Site directed mutagenesis, sequencing and transfections. HA-TLR7 cDNA was
purchased from Sino Biological (mouse TLR7; Cat # MG50962-NY with Gene
Bank Ref Seq number NM_133211.3). Mutation of the key cysteine residues in
TLR7 (Cys260, Cys263, Cys270, Cys273, Cys98, and Cys445) to alanine was
performed using the QuikChange Multi Site-Directed Mutagenesis kit (Cat #
200514, Agilent Technologies). Sequences of WT and mutant HA-TLR7 were
conﬁrmed by the Australian Genome Research Facility. Cells were transfected
using linear polyethyleneimine (PEI)24.
High-content ratiometric FRET imaging. Cells were plated and transfected in
suspension with 200 ng per well FRET biosensor DNA using PEI, in black, optically
clear 96-well plates for 48 hr. Prior to the experiment, cells were partially
serum-starved overnight in 0.5% FBS media. Fluorescence imaging was performed
using a high-content GE Healthcare INCell 2000 Analyzer with a Nikon Plan Fluor
ELWD 40×(NA 0.6) objective and FRET module as described22. For CFP/YFP
(CKAR) emission ratio analysis, cells were sequentially excited using a CFP ﬁlter
(430/24) with emission measured using YFP (535/30) and CFP (470/24) ﬁlters, and
a polychroic optimized for the CFP/YFP ﬁlter pair (Quad3). For GFP/RFP (EKAR)
emission ratio analysis, cells were sequentially excited using a FITC ﬁlter (490/20)
with emission measured using dsRed (605/52) and FITC (525/36) ﬁlters, and a
polychroic optimized for the FITC/dsRed ﬁlter pair (Quad4). Cells were imaged
every 100 s for 20 min (image capture of two ﬁelds of view in 12 wells per 100 s).
Data were analyzed using in-house scripts written for the FIJI distribution of Image
J34, as described24.
Quantiﬁcation of mRNA by QPCR. Cells were treated with imiquimod (10 μg/ml),
poly I:C (100 ng/ml), CpG (10 μg/ml), ssRNA (500 μg/ml) or catalase (1000 U/ml) for
24 h. Where indicated, cells were pre-treated with apocynin (300 μM), SOD (300 U/
ml) or baﬁlomycin A (100 nM) for 30min. RNA was extracted from the lung tissue of
mice that were treated with either DMSO (control), unconjugated gp91dstat (0.02mg/
kg, 0.2mg/kg), cholestanol conjugated-gp91dstat (0.02mg/kg, 0.2 mg/kg), scrambled
cholestanol conjugated gp91dstat (0.02mg/kg) and/or infected with Hk-x31 inﬂuenza
A virus (1 × 105 PFUs) 3 days post infection for the assessment of viral mRNA and
cytokine expression. The right lung lobe was placed in Eppendorf tubes containing a
mixture of Buffer RLT (Qiagen, USA) and β-mercaptoethanol (Sigma; 1%), which was
minced into small pieces using curved scissors. Following this, lung samples were
homogenized using the ultrasound homogenizer (Hielscher Ultrasonics GmBH,
Teltow, Germany) and centrifuged at 18407 × g for 5min. A 1:1 ratio of lysate was
mixed with 70% RNase free ethanol transferred to RNeasy spin columns (RNeasy
Minikit; Cat # 74104, Qiagen). Samples were spun at 10,000 rpm for 15 s and then
washed with Buffer RW1. After discarding the ﬂow-through, 5 μl of DNase I (Cat #
79254, Qiagen) was mixed with 35 μl of Buffer RDD was pipetted directly onto the
membrane of the spin column and incubated at room temperature for 15min. Buffer
RPE was added and centrifuged for 9391 × g for 15 s. After discarding the ﬂow-
through, Buffer RPE was re-added and spun for 9391 × g for 2 min. An additional
spin at 18407 × g for 1min was done to remove residual ﬂow-through from the spin
column. Finally, RNase free water was added and centrifuged to elute the RNA into
an Eppendorf tube. RNA samples were measured using the Nanodrop 1000 Spec-
trophotometer (Thermo Scientiﬁc, USA). cDNA synthesis was performed using the
High-Capacity cDNA Reverse Transcription Kit (Cat # 4368814, Applied Biosystems,
Foster City, CA, USA) using 1.0–2.0 μg total RNA. RNA was added to a mixture of
reagents in the High-Capacity cDNA RT kit to make a ﬁnal volume of 20 μl. This was
transcribed using the BioRad MycyclerTM thermal cycler (BioRad, USA) at the fol-
lowing settings: 25 °C for 10min, 37 °C for 120min, 85 °C for 5min and 4 °C at rest.
Samples were stored at −20 °C prior to use. Quantitative polymerase chain reaction
was carried out using the TaqMan Universal PCR Master Mix (Cat # 4304437,
Applied Biosystems, Foster City, CA, USA) or SYBR Green PCR Master Mix (Cat #
4367659, Applied Biosystems, Foster City, CA, USA) and analyzed on ABI Step One
TM and StepOnePlusTM Real-time PCR Systems (Perkin-Elmer Applied Biosystems,
Foster City, CA, USA). The PCR primers for TNF-α, IL-1β, IFN-β and IL-6 were
included in the Assayon- Demand Gene Expression Assay Mix (see Supplementary
Table 2, Applied Biosystems, Foster City, CA, USA). Additionally, a custom designed
forward and reverse primer of the segment 3 polymerase (PA) of inﬂuenza virus was
used to measure viral titers (Supplementary Table 2). The PCR program run settings:
50 °C for 2min, followed by 95 °C for 1 h, then 95 °C for 15 s + 60 °C for 60 s + plate
read (40 cycles). Quantitative values 129 were obtained from the threshold cycle (Ct)
number. Target gene expression level was normalized against 18 s or GAPDH mRNA
expression for each sample and data was expressed relative to the control.
ELISA and multiplex immunoassay. Protein levels of IFN-β (VeriKine HM mouse
IFN β Serum ELISA kit; Cat # 42410-1, PBL Assay Science), IL-1β (Quantikine
ELISA Mouse IL-1β/IL-IF2; Cat # MLB00C, R&D Systems), TNF-α (Quantikine
ELISA Mouse TNF α, Cat # MTA00B, R&D Systems), and IL-6 (Quantikine
ELISA Mouse IL-6, Cat # M6000B, R&D Systems) secreted into the BALF of
HKx31-infected (1 × 104 PFUs) WT and NOX2−/y mice were measured using
ELISAs and performed using commercially available kits according to the
manufacturer’s instructions. The cytokine titers in samples were determined by
plotting the optical densities using a 4-parameter ﬁt for the standard curve.
Antibody determination. Serum and BALF levels of various antibody isotypes
(IgA, IgE, IgG1, Ig2a, IgG2b, IgG3, IgM, and total IgG) were quantiﬁed in
HKx31-infected (1 × 104 PFUs) WT and NOX2−/y mice using the ProcartaPlex
Multiplex Immunoassay (Mouse Isotyping 7plex, Cat # EPX070-2815-901,
eBioscience) according to the manufacturer’s instructions. Brieﬂy, antibody-
conjugated magnetic beads were added into each well of a 96-well plate. Antibody
standards were serially diluted (1:4) in universal assay buffer to construct a 7-point
standard curve. Serum and BALF samples (diluted 1:20,000 in universal assay
buffer) and/or standards were added to appropriate wells of the 96-well plate
containing the antibody-conjugated magnetic beads. Following this, a detection
antibody mix was added to each well and the plate was incubated for 30 min at
room temperature on a microplate shaker (500 rpm) in the dark. After washing, a
reading buffer was added to all wells. The plate was read by a Magpix multiplex
reader (Luminex, USA) with xPONENT software (Luminex, USA). Procartaplex
Analyst 1.0 software (eBioscience, USA) was used to interpolate serum and BALF
antibody concentrations in each sample from the standard curve.
Statistical analysis and image analysis. In order to quantify the ﬂuorescence
microscopy data, images acquired from confocal systems were analyzed in
Image J. Approximately 100–150 cells per treatment group from at least three
independent experiments were analyzed unless otherwise stated in the ﬁgure legend
to calculate the ﬂuorescence in each cell, which was then averaged and expressed as
a percentage of the area ﬂuorescence. All statistical tests were performed using
GraphPad Prism (GraphPad Software Version 6.0, San Diego CA, USA). P< 0.05
was taken to indicate signiﬁcance. For isolated cell culture work, n is representative
of a separate experiment where cells were used from a different passage.
Chemicals. Imiquimod (Cat # tlrl-imq, Invivogen), HMW poly I:C (Cat # tlrl-pic,
Invivogen), and CpG ODN (Cat # tlrl-1668, Invivogen) were dissolved in
endotoxin-free water and prepared as stock solutions of 5–10 mg/ml in aliquots of
30 and 100 µl and stored at −20 °C. ssRNA (Cat # tlrl-lrna40, Invivogen) was
dissolved in endotoxin-free water and prepared as a stock solution of 5 mM in
aliquots of 50 µl and stored at −20 °C. Dynasore (Cat # D7693, Sigma) (freshly
prepared on the day) was dissolved in DMSO (100%) and prepared as 10 mM stock
solutions. FBS (Cat # 12003 C, Sigma) was stored in 50 ml aliquots at −20 °C.
Penicillin–streptomycin solution (Cat # P4333, Sigma) was stored at −20 oC.
SOD (Cat # S2515, Sigma) was dissolved in distilled water and prepared as stock
solutions (10 μl) of 30,000 units per ml and stored at −20 °C. OxyBURST Green
H2HFF bovine serum albumin (BSA) (Cat # 1329, Molecular probes, Life
Technologies) and LysoTracker Deep Red (Cat # L12492, Molecular probes,
Life Technologies) in stock solutions (1 mg/ml) were generated immediately before
use by dissolving in PBS. Baﬁlomycin A (from Streptomyces, Cat # B1793, Sigma)
was prepared as a stock solution of 100 μM in aliquots of 10 μl and stored at −20 °
C. Apocynin (4′-Hydroxy-3′-methoxy acetophenone, Cat # A10809, Sigma) made
freshly on the day of use and gp91dstat (Cat # AS-63818, Anaspec) were prepared
as stock solutions of 100 and 50 mM respectively, in 100% DMSO. Phorbol
dibutyrate (Cat # P1239, Sigma) was dissolved in 100% DMSO as 10 mM stocks
and made fresh on the day of use. Catalase (Cat # C1345, Sigma) was prepared
as stock solutions of 106 U/ml in distilled water and stored at −20 oC. MitoSOX
(Cat # M3600850, Molecular Probes, Life Technologies) was prepared at 5 mM by
dissolving the contents (50 μg) of one vial of MitoSOX mitochondrial superoxide
indicator (Component A) in 13 μl of DMSO. Xanthine oxidase (Cat # X1875,
Sigma) was prepared fresh on the day by dissolving in distilled water to 30 U/ml
and xanthine (Cat # X0626, Sigma) was prepared as a stock of 100 mM in 0.1 M
NaOH. ML171 (Cat # 492002, Calbiochem).
Antibodies for inﬂuenza nucleoprotein (mAb to Inﬂuenza A Virus
Nucleoprotein [AA5H]; Cat # 120-20343, AbCAM), early endosome antigen 1
(Cat # 120-02900, AbCAM), mouse anti-gp91phox (Cat # 611415, BD
Transduction Laboratories, Puriﬁed Mouse Anti gp91[phox] Clone 53/gp91[phox]
(RUO), rabbit anti-TLR7 (Cat # NBP2-24906, Novus Biologicals), rabbit
anti-p47phox antibody (Cat # sc14015, Santa Cruz), FITC goat anti-mouse IgG
(Cat # A-11029, Invitrogen), goat anti-rabbit alexa 594 (Cat # A-11037,
Invitrogen), goat anti-rabbit far red 647 (Cat # A-21244, Invitrogen), and DAPI
(Cat # H-1200, Vector Laboratories) were stored at −20 °C.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon request.
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